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Purpose: The clinical usefulness of hyaluronic acid (HA) instillation during visual in-
ternal urethrotomy (VIU) for decreasing the incidence of recurrent urethral stricture 
was assessed.
Materials and Methods: Twenty-eight patients were treated by VIU with HA in-
stillation between May 2007 and June 2009. After insertion of a Foley catheter following 
urethrotomy, HA was instilled via an 18-gauge tube catheter between the urethral lu-
men and Foley catheter. Seventeen cases were analyzed retrospectively 12 months 
postoperatively. We evaluated the success rate of this procedure by comparing retro-
grade urethrography (RGU) results, maximum flow rates, and postvoid residual urine 
volumes preoperatively and 3 and 12 months postoperatively. Success was defined as 
either a maximum flow rate of at least 15 ml/s or no visible urethral stricture on RGU 
at 12 months postoperatively.
Results: Total success rates were 76.5% (13/17) and 52.9% (9/17) at 3 and 12 months 
postoperatively, respectively. By etiology, success rates at 3 and 12 months post-
operatively, respectively, were 66.7% and 33.3% for inflammation, 66.7% and 50.0% 
for trauma, and 83.3% and 66.7% for unknown causes. Success rates were 63.6% for 
strictures less than 10 mm in length and 33.3% for strictures of 10 mm or more in length 
at 12 months postoperatively. Success rates were 61.5% for single strictures and 25% 
for multiple strictures at 12 months postoperatively.
Conclusions: The success rate of VIU with HA instillation was not better than that ob-
served in the literature for conventional VIU.
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INTRODUCTION
Urethral stricture is a common cause of lower urinary tract 
symptoms in patients. There are various causes of urethral 
stricture, for example, trauma, urethral catheterization, 
urologic instrumentation, and sexually transmitted dis-
eases [1]. 
　Treatment depends on the localization, length, and type 
of the stricture [2]. The most common technique for the 
management of urethral strictures is visual internal ure-
throtomy (VIU), because it is an easy, minimally invasive 
technique. VIU was first performed by Hans Sachse in 
1971. Dilatation, laser urethrotomy, and permanent ure-
thral stent applications have also been used [3].
　VIU is the appropriate choice of treatment for urethral 
strictures; however, one shortcoming of this technique is 
the frequent recurrence of stricture. The short-term suc-
cess rate of VIU varies from 39% to 73% for strictures short-
er than 1.5 cm, whereas the long-term recurrence rate is 
26.9% to 56% [4-6]. Self-catheterization, intralesional in-
jection of steroids, and mitomycin-C have been used to re-
duce and prevent recurrences [7-9]. Submucosal injection 
of mitomycin-C reduces the stricture recurrence rate after 
internal urethrotomy, because mitomycin-C has anti-fi-
broblast and anti-collagen properties [7,8]. Steroids are 
known to decrease the accumulation of collagen fibers and Korean J Urol 2010;51:853-857
854 Kim et al
TABLE 1. Success rates according to the etiology, length, number,
and site of urethral stricture in patients
No. 
of cases 
Success rate 
at 3 mo
Success rate at
12 mo
Total 17 13/17 (76.5) 9/17 (52.9)
Etiology
　Inflammation (%)   3 (17.6) 2/3 (66.7) 1/3 (33.3)
　Trauma (%)   6 (35.3) 4/6 (66.7) 3/6 (50)
　Post-TUR (%)   2 (11.8) 2/2 (100) 1/2 (50)
　Unknown (%)   6 (35.3) 5/6 (83.3) 4/6 (66.7)
Length of site
　＜10 mm (%) 11 (64.7) 9/11 (81.8) 7/11 (63.6)
　≥10 mm (%)   6 (35.3) 4/6 (66.7) 2/6 (33.3)
Stricture number
　Single (%) 13 (76.5) 10/13 (76.9) 8/13 (61.5)
　Multiple (%)   4 (23.5) 3/4 (75.0) 1/4 (25.0)
Site of stricture
　Penile (%)   4 (23.5) 3/4 (75.0) 1/4 (25.0)
　Bulbous (%) 12 (70.6) 10/12 (83.3) 8/12 (66.7)
　Membranous (%) 1 (5.9) 0/1 (0) 0/1 (0)
TUR: transurethral resection
fibroblasts, which results in the inhibition of fibroblast pro-
liferation in wound tissue [9-11].
　Lim et al reported that the efficacy of a hyaluronic acid 
(HA) and carboxymethylcellulose (CMC) bioresorbable 
membrane that reduced postoperative adhesions im-
proved with the intraoperative coadministration of a neu-
rokinin 1 receptor antagonist in a rat model [12]. Da-Silva 
et al reported that human urethral stricture tissue has a 
low level of HA and a high level of dermatan sulfate, which 
suggests that administration of HA into stricture sites 
might decrease the possibility of recurrence [13]. Through 
a similar mechanism, the authors hypothesized that 
HA/CMC would decrease fibrotic inflammation or the ad-
hesion of incised tissue in VIU. Currently, bioresorbable 
membranes composed of HA/CMC effectively prevent in-
tertissue adhesion. The physical barriers Seprafilmtm
TM 
Adhesion Barrier (Genzyme Biosurgery, Cambridge, MA, 
USA), Interceed
® Absorbable Adhesion Barrier (Ethicon, 
Somerville, NJ, USA), and ADEPT
® Adhesion Reduction 
Solution (Baxter Healthcare Corporation, Deerfield, IL, 
USA) are the only approved methods for preventing ab-
dominal and pelvic adhesions in the United States. 
Because the solution type, as opposed to the membrane 
type, is much preferred for spreading on incised tissues, we 
chose to use a mixed solution of HA/CMC (Guardix
®; 
Biorane, Seoul, Korea), which has been shown to sig-
nificantly reduce postsurgical adhesion [14]. The aim of 
this study was to assess the clinical usefulness of urethral 
instillation of a mixed solution of HA/CMC during VIU for 
decreasing the incidence of recurrent urethral strictures. 
MATERIALS AND METHODS
Between May 2007 and June 2009, 28 patients with a diag-
nosis of urethral strictures and treated with VIU were en-
rolled in the study. Patients with a history of urethral sur-
gery were excluded.
　In a total of 17 patients, the etiology was identified as in-
flammation in 3 (17.6%), trauma in 6 (35.3%), unknown in 
6 (35.3%), and post-transurethral resection (TUR) in 2 
(11.8%). Regarding stricture length, 11 patients (64.7%) 
had a 10 mm or shorter stricture, and 6 patients (35.3%) 
had a 10 mm or longer stricture. Regarding number of sites, 
4 patients had multiple strictures (23.5%), and 13 patients 
had a single stricture (76.5%). Regarding stricture loca-
tion, 4 patients (23.5%) had a stricture at the penile ure-
thra, 12 (70.6%) at the bulbous urethra, and 1 (5.9%) at the 
membranous urethra (Table 1).
　VIU at the 12 or 6 o’clock position was performed under 
spinal anesthesia using a 21 F Storz urethrotome with a 
straight cold knife. After urethrotomy, an 18 F Foley cathe-
ter was inserted into the bladder through the urethra. 
Guardix
® (1.5 ml) was then instilled via an 18-gauge tube 
catheter between the urethral lumen and the Foley cathe-
ter after about 5 minutes of subcoronal compression to 
spread the Guardix
® solution evenly in the incised urethra. 
　The Foley catheter was removed 2 weeks after the VIU 
was performed. The patients returned 3 and 12 months af-
ter surgery to undergo uroflowmetry and an examination 
of postvoid residual urine. We compared preoperative and 
postoperative values, including retrograde urethrography 
(RGU) results, maximum flow rates, and postvoid residual 
urine volumes. Success was defined as a maximal velocity 
of at least 15 ml/s by uroflowmetry or no visible urethral 
stricture by RGU. Before 12 months postoperatively, VIU 
was considered to have failed if a patient required another 
operation or additional procedures, such as urethral 
dilatation.
　This study retrospectively analyzed 17 patients who had 
undergone one VIU procedure; 11 cases were excluded be-
cause of the lack of follow-up 12 months postoperatively. 
RESULTS
The mean age of the patients was 53.1±16.5 years (range, 
18-83 years). Only 2 patients had benign prostatic hyper-
plasia. The total success rates at 3 and 12 months post-
operatively were 76.5% (13/17) and 52.9% (9/17), re-
spectively (Table 1). The maximal flow rate, average flow 
rate, and postvoid residual urine volume at 3 and 12 
months postoperatively were 17.9 and 16.7 ml/s, 11.6 and 
9.8 ml/s, and 23.1 and 18.2 ml/s, respectively (Table 2). By 
etiology, success rates were 33.3% (1/3) for inflammation, 
50% (3/6) for trauma, 66.7% (4/6) for unknown causes, and 
50% (1/2) for post-TUR at 12 months postoperatively. By 
stricture length, success rates were 63.6% for strictures 
less than 10 mm and 33.3% for strictures of 10 mm or more 
at 12 months postoperatively. By number of sites, the suc-
cess rates were 61.5% for single strictures and 25% for mul-
tiple strictures at 12 months postoperatively. By site of 
stricture, the success rates were 25% for the penile urethra, Korean J Urol 2010;51:853-857
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TABLE 2. Changes (Mean±SD) in Qmax, Qave, and postvoid 
residual urine volume at 3 and 12 months postoperatively
Preoperative 
Postoperative, 
3 mo
Postoperative, 
12 mo
Qmax (ml/s) 7.7±4.8 17.9±6.2 16.7±4.9
(p＜0.001)
a (p＜0.001)
a
Qave (ml/s) 3.8±2.0 11.6±4.5   9.8±4.6
(p＜0.001)
a (p＜0.001)
a
RU (ml) 80±83 23.1±40.5 18.2±22.8
(p＜0.05)
a (p＜0.05)
a
SD: standard deviation, RU: residual urine, Qmax: maximal flow
rate, Qave: average flow rate. 
a: compared with preoperative data
66.7% for the bulbous urethra, and 0% for the membranous 
urethra at 12 months postoperatively (Table 1).
　Of the 8 failed cases, the maximum uroflow rate was 
greater than 15 ml/s in 4 cases (average maximal flow rate, 
19.8 ml/s) at 3 months postoperatively; however, these pa-
tients did not meet the criteria for success at 12 months 
postoperatively. These 4 patients, who had an average 
maximal flow rate of 11 ml/s (range, 8-13 ml/s) and an aver-
age postvoid residual urine volume of 31.3 ml 12 months 
postoperatively, refused another operation because their 
daily activities were not adversely affected. One patient 
who had difficulty voiding also refused another reoperation 
for urethral stricture because of old age (83 years). Two pa-
tients underwent a repeat VIU and perineal urethroplasty. 
One patient was lost to follow-up after the 12-month post-
operative visit. Postoperative complications from VIU con-
sisted of hematuria in 2 patients, which did not require ad-
ditional procedures. No HA/CMC-related complications 
were observed after urethral instillation of Guardix
®.
DISCUSSION
VIU is the primary treatment option for patent urethral 
stricture because it is a simple and effective treatment. 
However, the frequent stricture recurrence rate and the 
need for additional surgery are shortcomings of this 
procedure. Byun and Song reported a VIU success rate of 
94%; 46% of all patients needed only one surgery, 54% need-
ed a second surgery, and 21% needed a third surgery [1]. 
The average number of times a patient underwent VIU was 
2.13. Chung et al reported a success rate of 64.5% for pa-
tients who underwent surgery only once, 42.4% for patients 
who underwent surgery twice, and 23.5% for patients who 
underwent surgery 3 times [15]. In this study, the success 
rates at 3 and 12 months postoperatively were 76.5% and 
52.9%, respectively. The short-term results were the same 
as or better than those observed in the literature for con-
ventional VIU. However, the long-term results were clear-
ly not better than those observed in the literature for con-
ventional VIU. 
　Factors that influence the success rate of VIU include the 
length and location of the strictured urethra. Byun and 
Song reported that all surgeries failed when the length of 
the stricture was greater than 2.5 cm, that 41% of all pa-
tients with a stricture length of 0.5 to 1.5 cm underwent a 
second VIU, and that 71% of all patients with a stricture 
length of 1.5-2.5 cm underwent a second VIU [1]. The aver-
age number of VIUs per patient was 1.49 cm for stricture 
lengths of 0.5-1.5 cm and 2.46 cm for stricture lengths of 
1.5-2.5 cm. These data indicate that the longer the stric-
ture, the greater the recurrence rate and the greater the 
number of VIU procedures required. Huh et al reported 
that the success rate of the first VIU was 81.8% for stricture 
lengths of 0.5 to 1.0 cm and 33.3% for stricture lengths of 
1.6 to 2.0 cm [2]. In our study, the success rate was 63.6% 
for stricture lengths of less than 10 mm and 33.3% for stric-
ture lengths of 10 mm or more. In our study, as in the liter-
ature, the success rate of VIU was better for short strictures 
than for longer strictures. However, 2 of the 4 failed cases 
who had long strictures (range, 15-70 mm) refused to un-
dergo another operation. Although these 2 cases did not 
meet the criteria for success at 12 months postoperatively, 
their daily lives were not adversely affected by their refusal 
of another operation. The clinical success rate associated 
with long strictures in the current study was thought to be 
better than the results observed in the literature; however, 
the findings should be confirmed in a large-scale, random-
ized controlled study.
　Regarding stricture location, Huh et al reported a 
first-VIU success rate of 66.7% for penile urethra stric-
tures, 65.2% for bulbous urethra strictures, and 50% for 
membranous urethra strictures [2]. Chung et al reported 
higher success rates for bulbous urethra strictures than for 
penile urethra strictures and for short strictures than for 
long strictures [15]. In our study, success rates were 25% 
for penile urethra strictures, 66.7% for bulbous urethra 
strictures, and 0% for membranous urethra strictures; 
these rates are similar to those observed in the literature. 
Regarding the number of strictures, success rates were 
61.5% for single strictures and 25% for multiple strictures, 
in agreement with data in the literature. 
　Much effort has been undertaken to improve the success 
rate of urethra stricture surgery and to decrease the re-
currence rate of stricture. Over the past 20 years, improve-
ments in endoscopic surgery have contributed to the suc-
cess rate of urethral stricture surgery [10,11,16-18]. 
Triamcinolone, mitomycin-C, transforming growth factor 
beta oligodeoxynucleotide, and gene therapy-such as re-
combinant adenovirus and retrovirus gene transfer-have 
also been used as adjuvant treatment [17,18].
　Mazdak et al reported the effects of mitomycin-C on ante-
rior urethral strictures, and Shin et al reported the effects 
of mitomycin-C on urethral strictures in the rat [7,8]. 
Mitomycin-C was reported to have anti-replication proper-
ties in animal and clinical studies. These studies suggest 
that mitomycin-C might inhibit the renewal of the epi-
thelium and synthesis of collagen secreted by fibroblasts 
in the affected urethra, which prevents scar formation and 
subsequently causes restricture.Korean J Urol 2010;51:853-857
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　Gücük et al used a steroid-coated (triamcinolone aceto-
nide 1%) 18 F hydrophilic dilatation catheter in post-VIU 
patients [10]. The steroids, which induce a fibroblast re-
action, suppressed (experimentally and clinically) a de-
crease in the accumulation of collagen fibers and fibro-
blasts and inhibited the proliferation of fibroblasts in 
wound tissue. These effects suggest that the local admin-
istration of steroids may prevent wound contraction, and 
thus recurrence, in patients treated for urethral strictures. 
The beneficial effects of steroids might also positively affect 
outcomes after hypospadias repair and urethroplasty. 
Furthermore, Jeon and Shim performed VIU with an 
Nd:YAG laser and triamcinolone injection, which resulted 
in a high success rate of 82.1% [11]. No specific complica-
tions or adverse effects were observed.
　Regardless of its etiology, urethral stricture can cause 
the formation of scar tissue, which can decrease the caliber 
of the urethral lumen and result in stricture. Regulation 
of the extracellular matrix plays an important role in tissue 
development, remodeling, and wound healing. Da-Silva et 
al, who proposed the theoretical possibility that un-
desirable scar tissue could be prevented pharmacologi-
cally, reported that the HA concentration was about 50% 
lower in strictured human bulbous urethra than in normal 
urethra [13]. It was suggested that the low concentration 
of HA and total glycosaminoglycans in urethral strictures 
may account for the undesirable biomechanical properties 
of urethral scar tissue. Therefore, the authors hypothe-
sized that application of HA/CMC to the incised tissue of 
urethral strictures might decrease the amount of scar tis-
sue and result in less adhesion between incised scar tissue.
　HA is thought to create a liquid-type barrier. The viscous 
solution, known as Sepracoat (Genzyme Corporation, 
Cambridge, MA, USA), was developed for use as a coating 
during surgery to protect tissues against operative trauma. 
However, this agent is absorbed rapidly and must be used 
within a crucial time period of 36 h to prevent adhesion for-
mation [19]. As a result, it was shown to have only moderate 
efficacy against the formation of de novo adhesion, which 
limits its widespread use [20]. To overcome these limi-
tations, HA was modified by combining it with CMC, and 
new HA derivatives have been obtained in the form of a re-
sorbable solution. The HA/CMC solution is a highly vis-
cous, hydrated suspension because of the cross-linked re-
action between the functional groups of the HA molecules; 
therefore, its residence time at the injured surface is longer 
than that of the original form of HA. 
　Guardix
® is a mixed solution of HA and CMC that serves 
as a membrane barrier. The modified liquid barrier is 
formed in situ by spraying the solution onto injured sites 
that are prone to adhesion formation. This highly viscous 
solution adheres to tissue and is hydrolyzed, is absorbed, 
and undergoes renal excretion several days after appli-
cation. For these reasons, Guardix
® was chosen for its an-
ti-adhesion effects to supply HA to the incised stricture tis-
sue in the current study. Park et al reported that the 
HA/CMC solution decreased the overall incidence of post-
operative adhesions and that it appears to be superior to 
oxidized regenerated cellulose membranes because this 
sprayable solution is easy to use and is suitable for site-spe-
cific adhesion prevention after multifocal injuries [21]. 
Kim et al reported that using an HA/CMC solution with 
continuous ambulatory peritoneal dialysis (CAPD) cathe-
ter insertion is an effective method for reducing the in-
cidence of greater omental adhesions and the rate of reoper-
ation for catheter reposition [22].
　In our study, VIU was unsuccessful in one case that was 
caused by a penetrating injury with a sharp object that re-
sulted in membranous urethral transaction and intra-
peritoneal bladder rupture. Therefore, VIU is not expected 
to achieve satisfactory results in cases of extensive injury 
and membranous urethral injury.
　The aim of this retrospective, cross-sectional study was 
to determine the usefulness of the injection of HA/CMC for 
preventing the recurrence of urethral stricture after VIU. 
Some shortcomings of this study included the absence of 
a control group and the small number of patient groups. The 
short-term results were the same as or better than those 
observed in the literature for conventional VIU. However, 
the long-term results were clearly not better than those ob-
served in the literature for conventional VIU. The authors 
believe that some positive outcomes resulted from this 
procedure. For example, failed cases with longer strictures 
did not require additional clinical procedures for voiding 
problems. Thus, we suggest that a large-scale, controlled 
trial be conducted with long-term follow-up to determine 
the efficacy and usefulness of HA/CMC urethral instil-
lation during VIU compared with that of VIU without HA/ 
CMC instillation. We recommend that a large-scale, multi-
center, randomized controlled trial be conducted in pa-
tients who have undergone a first VIU for anterior urethral 
stricture.
CONCLUSIONS
This study was designed to evaluate whether the urethral 
instillation of HA/CMC during VIU would decrease the re-
currence rate of urethral stricture. Unfortunately, the pro-
cedure did not demonstrate a favorable success rate 12 
months postoperatively compared with outcomes of con-
ventional VIU reported in the literature. However, because 
of the limitations of this retrospective study and the possi-
bility that the success rate would be better in a select pa-
tient population, we suggest that a large-scale, randomized 
controlled trial be conducted in a larger number of patients 
with long-term follow-up to examine the efficacy and use-
fulness of HA/CMC urethral instillation with VIU.
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